Sandoz, a company owned by Swiss srug maker Novartis AG (NVS), said that the U.S. Food and Drug Administration or FDA has accepted its Biologics License Application for its proposed biosimilar to Amgen Inc.'s (AMGN) U.S.-licensed Neulasta or pegfilgrastim - a recombinant human granulocyte colony-stimulating factor or G-CSF.
Sandoz is seeking approval for the same indication as the reference product. Pegfilgrastim is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in patients with cancer (non-myeloid) who receive chemotherapy that can cause fever and a low blood cell count, known as febrile neutropenia.
In the U.S., the incidence of febrile neutropenia is estimated to be more than 60,000 a year, accounting for nearly eight cases per 1,000 cancer patients. About 1.6 million people per year in the U.S. develop non-myeloid cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.